Published in Lancet on April 25, 1987
Mesothelioma: cases associated with non-occupational and low dose exposures. Occup Environ Med (1999) 1.74
Role of asbestos and other fibres in the development of diffuse malignant mesothelioma. Thorax (1990) 1.46
Mineral fibres, fibrosis, and asbestos bodies in lung tissue from deceased asbestos cement workers. Br J Ind Med (1990) 0.98
The health impact of nonoccupational exposure to asbestos: what do we know? Eur J Cancer Prev (2009) 0.87
Carving of non-asbestiform tremolite and the risk of lung cancer: a follow-up mortality study in a historical nephrite processing cohort. Occup Environ Med (2013) 0.77
Biological effects of naturally occurring and man-made fibres: in vitro cytotoxicity and mutagenesis in mammalian cells. Br J Cancer (1999) 0.76
Application of proteomics to soft tissue sarcomas. Int J Proteomics (2012) 0.75
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum (1993) 7.14
Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med (1979) 5.58
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Rheumatoid arthritis in Greek and British patients. A comparative clinical, radiologic, and serologic study. Arthritis Rheum (1992) 3.92
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum (2005) 3.25
Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum (1999) 2.99
Understanding delay in response to symptoms of acute myocardial infarction. A compelling agenda. Circulation (1991) 2.14
Endobronchial metastases secondary to solid tumors: report of eight cases and review of the literature. Lung Cancer (2000) 2.11
Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J Immunol (1977) 2.06
The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis (1994) 2.03
Genetic differences between primary and secondary sicca syndrome. N Engl J Med (1979) 1.93
Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med (1979) 1.79
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome. Semin Arthritis Rheum (2000) 1.74
Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum (1982) 1.73
Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol (1993) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Hypokalaemic paralysis as the presenting manifestation of primary Sjögren's syndrome. Nephrol Dial Transplant (1994) 1.62
High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol (1987) 1.59
Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis (1985) 1.56
Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis (2006) 1.54
Lymphoma development in Sjögren's syndrome: novel p53 mutations. Arthritis Rheum (1999) 1.53
Sjögren's syndrome in patients with the CREST variant of progressive systemic scleroderma. J Rheumatol (1991) 1.51
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int (2000) 1.50
Quartz hemolysis as related to its surface functionalities. Environ Res (1981) 1.47
Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol (1979) 1.46
A risk assessment for exposure to glass wool. Regul Toxicol Pharmacol (1999) 1.45
Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol (2007) 1.44
Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma. Scand J Rheumatol (2011) 1.41
Antiphospholipid syndrome: clinical and therapeutic aspects. Lupus (1994) 1.39
The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol (2002) 1.39
Necrotizing vasculitis in Greece: clinical, immunological and immunogenetic aspects. A study of 66 patients. Br J Rheumatol (1997) 1.39
Chrysotile asbestos in the lungs of persons in New York City. Arch Environ Health (1971) 1.39
Gas chromatographs: health effects. Science (1976) 1.38
Respiratory manifestations in primary Sjögren's syndrome. A clinical, functional, and histologic study. Chest (1985) 1.37
Reasons for patients' delay in response to symptoms of acute myocardial infarction. CMAJ (1988) 1.37
Preliminary diagnostic criteria for Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 1.37
Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) (2000) 1.36
Kidney involvement in primary Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 1.33
Sjögren's syndrome association with HLA-Dw3. N Engl J Med (1977) 1.32
Consumer talcums and powders: mineral and chemical characterization. J Toxicol Environ Health (1976) 1.31
Diffuse fasciitis with eosinophilia. A clinicopathologic study. Am J Med (1980) 1.31
Sjögren's syndrome: a defect in reticuloendothelial system Fc-receptor-specific clearance. Ann Intern Med (1979) 1.29
Sjögren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med (1977) 1.27
Central nervous system involvement in Sjogren's syndrome. Ann Rheum Dis (2004) 1.26
HLA-DR expression by labial minor salivary gland tissues in Sjögren's syndrome. Ann Rheum Dis (1986) 1.25
Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum (1996) 1.23
Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum (1996) 1.23
Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J (2008) 1.21
Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum (1981) 1.21
Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J (2009) 1.21
Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology (1990) 1.19
Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögren's syndrome. Clin Exp Immunol (2007) 1.17
T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sjögren's syndrome. J Rheumatol (1991) 1.17
Endemic pleural disease associated with exposure to mixed fibrous dust in Turkey. Science (1982) 1.15
Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases. Ann Rheum Dis (2004) 1.14
Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med (1977) 1.14
Chemical characterization of uncoated asbestos fibers from the lungs of asbestos workers by electron microprobe analysis. J Histochem Cytochem (1972) 1.13
Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis (2006) 1.12
Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM (2000) 1.12
CBA/N X-linked B-cell defect prevents NZB B-cell hyperactivity in F1 mice. J Exp Med (1979) 1.12
Erythema nodosum: the underlying conditions. Clin Rheumatol (2000) 1.11
Renal tubular acidosis in primary Sjögren's syndrome. Clin Rheumatol (1992) 1.11
Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol (1995) 1.10
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) (2001) 1.10
Detection of anti-interferon antibodies in systemic lupus erythematosus. Clin Exp Rheumatol (1985) 1.10
Dendritic cell replacement in long-surviving liver and cardiac xenografts. Transplantation (1993) 1.10
Liver involvement in primary Sjögren's syndrome. Br J Rheumatol (1994) 1.09
Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) (2004) 1.09
Demonstration and identification of monoclonal proteins in the urine of patients with Sjögren's syndrome. Ann Rheum Dis (1985) 1.09
Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.09
Echocardiographic identification of cardiac abnormality in scleroderma and related disorders. Am J Med (1979) 1.09
Serological profiles in subgroups of patients with Sjögren's syndrome. Scand J Rheumatol Suppl (1986) 1.08
Modes of epithelial cell death and repair in Sjögren's syndrome (SS). Clin Exp Immunol (1998) 1.08
Asbestos exposure during brake lining maintenance and repair. Environ Res (1976) 1.08
Anticardiolipin antibodies in unselected autoimmune rheumatic disease patients. Clin Immunol Immunopathol (1987) 1.07
A study of workers exposed to asbestiform minerals in commercial talc manufacture. Environ Res (1973) 1.07
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) (1999) 1.06
CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome. Clin Exp Immunol (1999) 1.06
Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients. Lupus (1993) 1.06
"Lymphoid" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sjögren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum (2001) 1.06
Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease. Ann Rheum Dis (1999) 1.05
Prevalence of Sjögren's syndrome in a closed rural community. Ann Rheum Dis (1997) 1.05
Asbestos air pollution. Arch Environ Health (1972) 1.04
Peripheral neuropathies in Sjögren's syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun (2012) 1.04
CD5-expressing B lymphocytes in the blood and salivary glands of patients with primary Sjögren's syndrome. J Autoimmun (1988) 1.03
The spectrum of neurological involvement in Sjögren's syndrome. Br J Rheumatol (1990) 1.03
Sjögren's syndrome: autoimmune epithelitis. Baillieres Best Pract Res Clin Rheumatol (2000) 1.03
Oligoclonal immunoglobulins in patients with the acquired immunodeficiency syndrome. Clin Immunol Immunopathol (1985) 1.02
Presence of intracytoplasmic IgG in the lymphocytic infiltrates of the minor salivary glands of patients with primary Sjögren's syndrome. Clin Exp Rheumatol (1985) 1.01
The clinical picture of primary Sjögren's syndrome: a retrospective study. J Rheumatol (1983) 1.01
Detection of anti-Ro(SSA) antibodies in autoimmune diseases: comparison of five methods. Br J Rheumatol (1993) 1.01